Investigator-reported efficacy of Azelaic acid foam 15% in patients with papulopustular rosacea: Secondary efficacy outcomes from a randomized, controlled, double-blind, phase 3 trial

James A. Solomon, Stephen Tyring, Gerald Staedtler, Meike Sand, Richard Nkulikiyinka, Kaweh Shakery

Research output: Contribution to journalArticlepeer-review

Abstract

Papulopustular rosacea (PPR) is characterized by centrofacial papules and pustules commonly associated with erythema. To compare investigator-reported efficacy outcomes for azelaic acid (AzA) foam 15% versus vehicle foam in PPR, a randomized, vehiclecontrolled double-blind phase 3 clinical trial was conducted at 48 US sites. Participants received AzA foam or vehicle foam for 12 weeks. Secondary efficacy outcomes included change in inflammatory lesion count (ILC), therapeutic response rate according to investigator global assessment (IGA), and change in erythema rating. This study was comprised of 961 participants with PPR. The results support the therapeutic superiority of AzA foam over vehicle foam.

Original languageEnglish (US)
Pages (from-to)187-194
Number of pages8
JournalCutis
Volume98
Issue number3
StatePublished - 2016
Externally publishedYes

ASJC Scopus subject areas

  • Dermatology

Fingerprint

Dive into the research topics of 'Investigator-reported efficacy of Azelaic acid foam 15% in patients with papulopustular rosacea: Secondary efficacy outcomes from a randomized, controlled, double-blind, phase 3 trial'. Together they form a unique fingerprint.

Cite this